ARTICLE | Clinical News
EMA's CHMP recommended approval of Dupixent dupilumab (REGN668, SAR231893) from Sanofi (Euronext:SAN; NYSE:SNY) to treat moderate to severe atopic dermatitis. The human mAb targeting the alpha subunit...
EMA's CHMP recommended approval of Dupixent dupilumab (REGN668, SAR231893) from Sanofi (Euronext:SAN; NYSE:SNY) to treat moderate to severe atopic dermatitis. The human mAb targeting the alpha subunit...